Apyx Medical Corporation (NASDAQ:APYX) Short Interest Update

Key Points

• Apyx Medical Corporation reported a 26.0% decrease in short interest in August, dropping from 313,200 shares to 231,900 shares.
• The company's stock is currently trading at $2.13, with a market capitalization of $80.56 million and a negative PE ratio of -4.73.
• For the second quarter, Apyx Medical reported a revenue of $11.37 million, slightly below analysts' expectations of $11.69 million, maintaining an EPS of ($0.09).

Apyx Medical Corporation (NASDAQ:APYX - Get Free Report) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totaling 231,900 shares, a decline of 26.0% from the August 15th total of 313,200 shares. Based on an average daily volume of 88,400 shares, the short-interest ratio is presently 2.6 days. Approximately 0.7% of the company's shares are sold short. Approximately 0.7% of the company's shares are sold short. Based on an average daily volume of 88,400 shares, the short-interest ratio is presently 2.6 days.

Institutional Trading of Apyx Medical

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Silverberg Bernstein Capital Management LLC boosted its stake in shares of Apyx Medical by 38.7% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 896,736 shares of the company's stock valued at $2,018,000 after purchasing an additional 250,167 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in Apyx Medical by 2.8% during the first quarter. Nantahala Capital Management LLC now owns 3,258,048 shares of the company's stock worth $4,464,000 after acquiring an additional 88,248 shares in the last quarter. Kingsview Wealth Management LLC boosted its stake in Apyx Medical by 29.5% during the first quarter. Kingsview Wealth Management LLC now owns 175,095 shares of the company's stock worth $240,000 after acquiring an additional 39,850 shares in the last quarter. Citadel Advisors LLC boosted its stake in Apyx Medical by 130.6% during the fourth quarter. Citadel Advisors LLC now owns 66,355 shares of the company's stock worth $105,000 after acquiring an additional 37,582 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Apyx Medical by 27.9% during the fourth quarter. Northern Trust Corp now owns 132,251 shares of the company's stock worth $209,000 after acquiring an additional 28,865 shares in the last quarter. Institutional investors own 55.33% of the company's stock.

Apyx Medical Stock Performance

Apyx Medical stock traded up $0.05 on Friday, reaching $2.29. 66,704 shares of the stock were exchanged, compared to its average volume of 44,919. The company has a current ratio of 4.72, a quick ratio of 3.95 and a debt-to-equity ratio of 4.61. Apyx Medical has a twelve month low of $0.76 and a twelve month high of $2.73. The firm has a fifty day moving average price of $2.09 and a two-hundred day moving average price of $1.66. The stock has a market cap of $86.61 million, a PE ratio of -5.09 and a beta of 1.43.

Apyx Medical (NASDAQ:APYX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, meeting analysts' consensus estimates of ($0.09). The business had revenue of $11.37 million during the quarter, compared to analyst estimates of $11.69 million. Apyx Medical had a negative net margin of 37.11% and a negative return on equity of 158.22%. Apyx Medical has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Apyx Medical will post -0.68 EPS for the current year.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.